Claus Bachert, M.D., was the principal investigator of the SINUS-24 and SINUS-52 phase 3 trials, the results of which led to the FDA approval of Dupixent for use with other medicines to treat chronic rhinosinusitis with nasal polyposis (CRSwNP) in adults whose disease is not controlled.
SINUS-24 and SINUS-52 were 24- and 52-week trials, respectively, and evaluated Dupixent 300 mg every two weeks with standard-of-care mometasone furoate nasal spray (MFNS) compared to placebo injection plus MFNS. In these trials, Dupixent significantly improved key disease measures and met all primary and secondary endpoints. For the co-primary endpoints: a 57% and 51% improvement in nasal congestion/obstruction severity was observed compared to a 19% and 15% improvement with placebo in SINUS-24 and SINUS-52, respectively, and a 33% and 27% reduction in nasal polyps score was reported compared to a 7% and 4% increase with placebo in SINUS-24 and SINUS-52, respectively.
Claus Bachert MD PhD., is chief of the clinic and professor at the University Hospital of Ghent, Belgium, and also holds a position as professor at the Karolinska Institute, Stockholm, Sweden. He qualified from the University of Heidelberg, Germany, and trained in ENT-diseases and allergology in Mannheim and Düsseldorf. His research interests include the pathophysiology and management of diseases of the nose and sinuses such as allergic and non-allergic rhinitis, chronic rhinosinusitis and nasal polyposis. Specifically, he has worked on endotyping rhinosinusitis, innovative treatments such as biologicals for recalcitrant disease, and the role of Staphylococcus aureus in the inflammation of nasal polyp disease.
Dr. Bachert chairs the Upper Airways Research Laboratory at Ghent University, and has published over 550 peer-reviewed articles in international journals. Dr. Bachert received several national and international prizes, and two doctor honoris causa (Capital University Beijing, China, and Democritus University, Trace, Greece). Dr. Bachert forms part of the international guidelines ARIA (Allergic Rhinitis and its Impact on Asthma) and EPOS (European Position Paper on Sinusitis and Nasal Polyposis), served in the Board of EAACI and WAO, and was President of the German Allergy Society (DGAKI, 2007-2010) and Vice-President 2011-2016. He currently serves as Editor for the Journal of Allergy and Clinical Immunology.Source: CVENT